Oncology

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

05/16/2025

Excerpt from the Press Release: BOSTON, May 8, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase 1a clinical trial has received their initial dose of TTX-MC138. All cohorts have enrolled…

Read More

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

05/15/2025

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, with new IMNN-001 data to be highlighted in…

Read More

OmRx Oncology Initiates Phase 2 Trial of Oral PD-L1 Inhibitor OX-4224 in NSCLC

05/14/2025

Study will evaluate OX-4224 as a second-line monotherapy in patients with PD-L1–positive non-small cell lung cancer, expanding potential access to checkpoint inhibitors in low-resource settings Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–OmRx Oncology, or “OmRx,” a clinical-stage biopharmaceutical venture dedicated to expanding access to cancer immunotherapy worldwide, today announced the initiation of a Phase…

Read More

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

05/07/2025

Excerpt from the Press Release: BOSTON, May 1, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit…

Read More

BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors

04/11/2025

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that the first patient has been dosed with BBO-11818 in the Phase 1 KONQUER-101 trial for advanced solid tumors. BBO-11818 is an orally bioavailable small molecule…

Read More

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

03/27/2025

Excerpt from the Press Release: BOSTON, March 13, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase I clinical trial has unanimously approved opening of the fourth cohort of patients based on…

Read More

SKYLINEDX ANNOUNCES NEW STUDY DEMONSTRATING ENHANCED RISK STRATIFICATION FOR SENTINEL LYMPH NODE BIOPSY IN HEAD AND NECK MELANOMA USING THE ADVANCED MERLIN CP-GEP TEST

03/21/2025

Excerpt from the Press Release: ROTTERDAM, Netherlands and SAN DIEGO, March 12, 2025 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology and, inflammatory and infectious diseases, proudly announces the publication of a groundbreaking study titled “Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head…

Read More

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

03/19/2025

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, will highlight progress across its clinical pipeline, including continued advancement of…

Read More

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

03/12/2025

Excerpt from the Press Release: LEXINGTON, Mass.–(BUSINESS WIRE)– Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy. Agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, tumor microenvironment conditioning agents and…

Read More

Phoenix Molecular Designs Dosed First Patient in Dauntless-1, a Phase 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer

02/28/2025

PMD-026 is a first-in-class and best-in-class pan-RSK inhibitorFavorable mPFS demonstrated in Phase 1/1b as a monotherapy in RSK2-high metastatic breast cancer patients. Excerpt from the Press Release: SAN DIEGO and VANCOUVER, British Columbia, Feb. 20, 2025 (GLOBE NEWSWIRE) — Phoenix Molecular Designs (PhoenixMD), a female-founded clinical-stage precision oncology company focused on developing precise cancer therapeutics,…

Read More